ArticleTherapeutic advances in medical oncology2019

Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer.

Sol-Bi Shin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.